Delcath Systems (DCTH) Expected to Announce Earnings on Thursday

Delcath Systems (NASDAQ:DCTH) will likely be releasing its earnings data before the market opens on Thursday, March 6th. Analysts expect Delcath Systems to post earnings of ($0.10) per share and revenue of $14.96 million for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link.

Delcath Systems Trading Down 5.8 %

DCTH opened at $13.35 on Tuesday. The company has a market cap of $426.85 million, a P/E ratio of -9.89 and a beta of 0.86. The business’s 50-day moving average price is $14.28 and its 200-day moving average price is $11.56. Delcath Systems has a 12 month low of $3.70 and a 12 month high of $16.97.

Analyst Ratings Changes

A number of research analysts recently issued reports on DCTH shares. Craig Hallum boosted their price target on Delcath Systems from $18.00 to $21.00 and gave the company a “buy” rating in a report on Friday, January 17th. HC Wainwright restated a “buy” rating and set a $22.00 price target on shares of Delcath Systems in a report on Tuesday, January 14th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $22.25.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.